Logo image of GNTA

GENENTA SCIENCE SPA - ADR (GNTA) Stock Fundamental Analysis

NASDAQ:GNTA - US36870W1009 - ADR

3.44 USD
-0.06 (-1.71%)
Last: 9/8/2025, 11:45:43 AM
Fundamental Rating

3

Overall GNTA gets a fundamental rating of 3 out of 10. We evaluated GNTA against 541 industry peers in the Biotechnology industry. GNTA has a great financial health rating, but its profitability evaluates not so good. GNTA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GNTA had negative earnings in the past year.
In the past year GNTA has reported a negative cash flow from operations.
GNTA had negative earnings in each of the past 5 years.
In the past 5 years GNTA always reported negative operating cash flow.
GNTA Yearly Net Income VS EBIT VS OCF VS FCFGNTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of -60.12%, GNTA is in line with its industry, outperforming 43.07% of the companies in the same industry.
Looking at the Return On Equity, with a value of -71.32%, GNTA is in line with its industry, outperforming 56.56% of the companies in the same industry.
Industry RankSector Rank
ROA -60.12%
ROE -71.32%
ROIC N/A
ROA(3y)-45.86%
ROA(5y)-36.67%
ROE(3y)-51.85%
ROE(5y)-41.34%
ROIC(3y)N/A
ROIC(5y)N/A
GNTA Yearly ROA, ROE, ROICGNTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

GNTA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GNTA Yearly Profit, Operating, Gross MarginsGNTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, GNTA has more shares outstanding
The number of shares outstanding for GNTA has been increased compared to 5 years ago.
GNTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GNTA Yearly Shares OutstandingGNTA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M
GNTA Yearly Total Debt VS Total AssetsGNTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

An Altman-Z score of 7.64 indicates that GNTA is not in any danger for bankruptcy at the moment.
The Altman-Z score of GNTA (7.64) is better than 80.78% of its industry peers.
GNTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.64
ROIC/WACCN/A
WACCN/A
GNTA Yearly LT Debt VS Equity VS FCFGNTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

GNTA has a Current Ratio of 6.89. This indicates that GNTA is financially healthy and has no problem in meeting its short term obligations.
GNTA has a better Current ratio (6.89) than 68.58% of its industry peers.
GNTA has a Quick Ratio of 6.89. This indicates that GNTA is financially healthy and has no problem in meeting its short term obligations.
GNTA's Quick ratio of 6.89 is fine compared to the rest of the industry. GNTA outperforms 68.76% of its industry peers.
Industry RankSector Rank
Current Ratio 6.89
Quick Ratio 6.89
GNTA Yearly Current Assets VS Current LiabilitesGNTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 23.70% over the past year.
EPS 1Y (TTM)23.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GNTA will show a decrease in Earnings Per Share. The EPS will decrease by -3.77% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-9.23%
EPS Next 2Y-3.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GNTA Yearly EPS VS EstimatesGNTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GNTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GNTA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNTA Price Earnings VS Forward Price EarningsGNTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNTA Per share dataGNTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

GNTA's earnings are expected to decrease with -3.77% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.77%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GNTA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENENTA SCIENCE SPA - ADR

NASDAQ:GNTA (9/8/2025, 11:45:43 AM)

3.44

-0.06 (-1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners10.37%
Inst Owner Change0%
Ins Owners27.5%
Ins Owner ChangeN/A
Market Cap62.92M
Analysts82.86
Price Target21.42 (522.67%)
Short Float %0.05%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.3
P/tB 4.3
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.85
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0
BVpS0.8
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -60.12%
ROE -71.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.86%
ROA(5y)-36.67%
ROE(3y)-51.85%
ROE(5y)-41.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.11%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.89
Quick Ratio 6.89
Altman-Z 7.64
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)114.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.63%
EPS Next Y-9.23%
EPS Next 2Y-3.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-141.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.31%
OCF growth 3YN/A
OCF growth 5YN/A